BMC Cancer (2001) 1:8 http://www.biomedcentral.com/1471-2407/1/8 study among white, black, and Asian women. J Natl Cancer Inst 1994, 86:589-99 10. Van't Veer P, Lobbezoo IE, Matin-Moreno JM, Guallar E, Gómez-Ara- cena J, Kardinaal AFM, Kohlmeier , Martin BC, Strain JJ, Thamm M, et al: DDT (dicophane) and postmenopausal breast cancer in Europe:Case-control study. BMJ 1997, 315:81-5 11. Hunter DJ, Hankinson SE, Laden F, Graham SM, Colditz A, Manson JE, Willett WC, Speizer FE, Wolff MS: Plasma organochlorine levels and the risk of breast cancer. N Engl J Med 1997, 18:1253-8 12. Lopez-Carillo L, Blair A, Lopez-Cervantes M, Cebrian M, Rueda C, Reyes R, Mohar A, Bravo JL: Dichlorodiphenyl trichloroethane serum levels and breast cancer risk: A case-control study from Mexico. Cancer Res 1997, 57:3728-32 13. Høyer AP, Grandjean P, Jørgensen T, Brock JW, Hartvig HB: Orga- nochlorine exposure and risk of breast cancer. Lancet 1998, 352:1816-1820 14. Moysich KB, Ambrosone CB, Vena JE, Shields PG, Mendola P, Kosty- niak P, Greizerstein H, Graham S, Marshall JR, Schisterman EF, et al: Environmental organochlorine exposure and postmenopau- sal breast cancer risk. Cancer, Epidemiology Biomarkers & Prevention 1998, 7:181-88 15. Dorgan JF, Brock JW, Rothman N, Needham LL, Miller R, Stephenson HE, Schussler N, Taylor PR: Serum organochlorine pesticides and PBCs and breast cancer risk: results from a prospective analysis (USA). Cancer Causes Control 1999, 10:1-11 16. Dewailly E, Dodin S, Verreault R, Ayotte P, Sauvé L, Morin J, Brisson J: High organochlorine body burden in women with estrogen receptor-positive breast cancer. J Natl Cancer Inst 1994, 86:232-4 17. Helzlsour KJ, Alberg AJ, Huang H-Y, Hoffman SC, Strickland PT, Brock JW, Burse VW, Needham LL, Bell DA, Lavigne JA, et al: Serum concentrations of organochlorine compounds and the subse- quent development of breast cancer. Cancer, Epidemiology, Bi- omarkers, & Prevention 1999, 8:525-532 18. Güttes S, Failing K, Neumann K, Kleinstein J, Georgii S, Brunn H: Chloroganic pesticides and polychlorinated biphenyls in breast tissue of women with benign and malignant disease. Environ, Contam, and Toxicol 1998, 35:140-147 19. Liljegren G, Hardell L, Lindström G, Dahl P, Magnuson A: Case-con- trol study on breast cancer and adipose tissue concentra- tions of congener specific polychlorinated biphenyls, DDE and hexachlorobenzene. Europ J Cancer Prev 1998, 7:135-140 20. Zheng T, Holford TR, Mayne ST, Tessari J, Owens SH, Zhang ZB, Du- brow R, Ward B, Carter D, Boyle P: Environmental exposure to hexachlorobenzene (HCB) and risk of female breast cancer in Connecticut. Cancer Epidemiology, Biomarkers & Prevention 1999, 8:407-411 21. Zheng T, Holford TR, Mayne ST, Ward B, Carter D, Owens PH, Di- brow R, Zahm SH, Boyle P, Archibeque S, et al: DDE and DDT in breast tissue and risk of female breast cancer. Am J Epidemiol 1999, 150:453-458 22. Aronson KJ, Miller AB, Woolcott CG, Sterns EE, McCready Likeey, LA DR, Fish EB, Hiraki GY, Holloway C, Ross T, et al: Breast adi- pose tissue concentrations of polychlorinated biphenyls and other organochlorines and breast cancer risk. Cancer, Epidemi- ology, Biomarkers & Prevention 2000, 9:55-63 23. Demers A, Ayotte P, Brisson J, Dodin S, Robert J, Dewailly E: Risk and aggressiveness of breast cancer in relation to plasma or- ganochlorine concentrations. Cancer, Epidemiology, Biomarkers & Prevention 2000, 9:161-166 24. Høyer AP, Jørgensen T, Brock JW, Grandjean P: Organochlorine exposure and breast cancer survival. J Clin Epidemiol 2000, 53:323-330 25. Pertschuk LP, Feldman JG, Yong-Doo K, Braithwaite L, Schneider F, Braverman AS, Axiotis C: Estrogen receptor immunocyto- chemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Spγ in frozen sections or cytosol-based ligand-binding assays. Cancer 1996, 77:2514-19 26. Brock JW, Burse VW, Ashley DL, Najam AR, Green VE, Korver MP, Powell MK, Hodge CC, Needham LL: An improved analysis for chlorinated pesticides and polychlorinated biphenyls (PCBs) in human and bovine sera using solid-phase extraction. J Anal Toxicol 1996, 20:528-36 27. Philipps DL, Pirkle JL, Burse VW, Bernert JT, Henderson O, Neddham LL: Chlorinated hydrocarbon levels in human serum: Effects of fasting and feeding. Arch Environ Contam Toxicol 1989, 18:495- 500 28. Cox DR: Regression models and life-tables (with discussion). JR Stat Soc 1972, 34:187-220 29. : SAS Technical Report P-217. SAS/STAT Software:The PHREG Procedure Version 6 SAS Institute, Cary, NC, USA 1991 30. Hildrith NG, Kelsey JL, Eisenfeld AJ, Li Volsi VA, Holford TR, Fisher DBL: Differences in breast cancer risk factors according to the estrogen receptor level of the tumor. J Natl Cancer Inst 1983, 70:1027-1031 31. Hislop TG, Coldman AJ, Elwood JM, Skippen DH, Kan L: Relation- ship between risk factors for breast cancer and hormonal status. Int J Epidemiol 1986469-476 32. Mc Tiernan A, Thomas DB, Johnson LK, Roseman D: Risk factors for estrogen receptor-rich and estrogen receptor-poor breast cancers. J Natl Cancer Inst 1986, 77:849-854 33. Stanford JL, Szkio M, Boring CC: A case-control study of breast cancer stratified by estrogen receptor status. Am J Epidemiol 1987, 125:184-194 34. Cooper JA, Rohan TE, Horsfall DJ, Tilley WD: Risk factors for breast cancer by receptor status:a population-based case- control study. Br J Cancer 1989, 59:119-125 35. Kreiger N, King WD, Rosenberg L, Clarke EA, Palmer JR, Shapiro S: Steroid receptor status and the epidemiolgy of breast can- cer. Ann.Epidemiol 1991, 1:513-523 36. Yoo KY, Tajima K, Miura S S: A hospital-based case-control study of breast-cancer risk factors by estrogen and proges- terone receptor status. Cancer, Causes & Control 1993, 4:39-44 37. Kelsey JL, Bernstein L: Epidemiology and prevention of breast cancer. Annu Rev Public Health 1996, 17:47-67 38. Nicholson RI RI: Why ER level may not reflect endocrine re- sponsiveness in breast cancer. Rev End Rel Cancer 1992, 40:252-8 39. Anderson J, Orntoft T, Poulson SH: Semiquantitative oestrogen receptor assay in formalin-fixed paraffin sections of human breast cancer tissue using monoclonal antibodies Br J Cancer 1986, 53:691-4 40. Snead DJR, Bell JA, Dixon AR: Methodology of immunohisto- chemical detection of oestrogen receptor in human breast carcinoma in formalin fixed paraffin embedded tissue: a comparison with frozen section morphology. Histopatholy 1993, 23:233-8 41. Goulding H, Pinder S, Cannon P: A new method for the assess- ment of oestrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol 1995, 26:291-4 42. King WJ, Greene GL: Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature 1984, 307:745-47 43. Gaskell DJ, Hawkins RA RA, Tesdale AL: The differing predictive values of oestrogen receptor assays for large breast cancers. Postgrad Med J 1992, 68:900-3 44. Robertson JFR, Bates K, Pearson D: Comparison of two oestro- gen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Br J Cancer 1992, 65:727- 30 45. Storm HH: Completeness of cancer registration in Denmark 1943-1966 and efficacy of record linkage procedures. Int J Epi- demiol 1988, 17:44-9 46. Fisherman K, Mouridsen HT: Danish Breast Cancer Co-opera- tive Group (DBCG). Acta Chir Scand, Suppl. 1984, 519:55-59 Pre-publication history The pre-publication history for this paper can be ac- cessed here: http://www.biomedcentral.com/content/backmatter/ 1471-2407-1-8-b1.pdf